Literature DB >> 34889384

Modified T cells as therapeutic agents.

Nathan Singh1.   

Abstract

Immunotherapy is now a well-established modality in the treatment of cancer. Although several platforms to redirect the immune response exist, the use of genetically modified T cells has garnered particular attention in recent years. This is due, in large part, to their success in the treatment of B-cell malignancies. Adoptively transferred T cells have also demonstrated efficacy in the treatment of systemic viral infections that occur following hematopoietic cell transplantation prior to immune reconstitution. Here we discuss the techniques that enable redirection of T lymphocytes to treat cancer or infection and the current indications for these therapies.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 34889384      PMCID: PMC8791139          DOI: 10.1182/hematology.2021000262

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  42 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

Authors:  Nathan Singh; Ted J Hofmann; Zachary Gershenson; Bruce L Levine; Stephan A Grupp; David T Teachey; David M Barrett
Journal:  Cytotherapy       Date:  2017-05-11       Impact factor: 5.414

3.  Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

Authors:  Noelle V Frey; Pamela A Shaw; Elizabeth O Hexner; Edward Pequignot; Saar Gill; Selina M Luger; James K Mangan; Alison W Loren; Alexander E Perl; Shannon L Maude; Stephan A Grupp; Nirav N Shah; Joan Gilmore; Simon F Lacey; Jos J Melenhorst; Bruce L Levine; Carl H June; David L Porter
Journal:  J Clin Oncol       Date:  2019-12-09       Impact factor: 44.544

4.  Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Noelle V Frey; Saar Gill; Elizabeth O Hexner; Stephen Schuster; Sunita Nasta; Alison Loren; Jakub Svoboda; Edward Stadtmauer; Daniel J Landsburg; Anthony Mato; Bruce L Levine; Simon F Lacey; Jan Joseph Melenhorst; Elizabeth Veloso; Avery Gaymon; Edward Pequignot; Xinhe Shan; Wei-Ting Hwang; Carl H June; David L Porter
Journal:  J Clin Oncol       Date:  2020-04-16       Impact factor: 44.544

5.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Authors:  Michael Wang; Javier Munoz; Andre Goy; Frederick L Locke; Caron A Jacobson; Brian T Hill; John M Timmerman; Houston Holmes; Samantha Jaglowski; Ian W Flinn; Peter A McSweeney; David B Miklos; John M Pagel; Marie-Jose Kersten; Noel Milpied; Henry Fung; Max S Topp; Roch Houot; Amer Beitinjaneh; Weimin Peng; Lianqing Zheng; John M Rossi; Rajul K Jain; Arati V Rao; Patrick M Reagan
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

6.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors:  Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

7.  c-Jun overexpression in CAR T cells induces exhaustion resistance.

Authors:  Evan W Weber; Elena Sotillo; Rachel C Lynn; David Gennert; Peng Xu; Zinaida Good; Hima Anbunathan; John Lattin; Robert Jones; Victor Tieu; Surya Nagaraja; Jeffrey Granja; Charles F A de Bourcy; Robbie Majzner; Ansuman T Satpathy; Stephen R Quake; Michelle Monje; Howard Y Chang; Crystal L Mackall
Journal:  Nature       Date:  2019-12-04       Impact factor: 49.962

Review 8.  Cytokines in CAR T Cell-Associated Neurotoxicity.

Authors:  Juliane Gust; Rafael Ponce; W Conrad Liles; Gwenn A Garden; Cameron J Turtle
Journal:  Front Immunol       Date:  2020-12-16       Impact factor: 7.561

9.  Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.

Authors:  Kevin R Parker; Elena Sotillo; Evan W Weber; Rachel C Lynn; Hima Anbunathan; John Lattin; Zinaida Good; Julia A Belk; Bence Daniel; Dorota Klysz; Meena Malipatlolla; Peng Xu; Malek Bashti; Sabine Heitzeneder; Louai Labanieh; Panayiotis Vandris; Robbie G Majzner; Yanyan Qi; Katalin Sandor; Ling-Chun Chen; Snehit Prabhu; Andrew J Gentles; Thomas J Wandless; Ansuman T Satpathy; Howard Y Chang; Crystal L Mackall
Journal:  Science       Date:  2021-04-02       Impact factor: 47.728

10.  CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Authors:  Terry J Fry; Nirali N Shah; Rimas J Orentas; Maryalice Stetler-Stevenson; Constance M Yuan; Sneha Ramakrishna; Pamela Wolters; Staci Martin; Cindy Delbrook; Bonnie Yates; Haneen Shalabi; Thomas J Fountaine; Jack F Shern; Robbie G Majzner; David F Stroncek; Marianna Sabatino; Yang Feng; Dimiter S Dimitrov; Ling Zhang; Sang Nguyen; Haiying Qin; Boro Dropulic; Daniel W Lee; Crystal L Mackall
Journal:  Nat Med       Date:  2017-11-20       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.